ImmunityBio Inc. (NASDAQ: IBRX) reported preliminary net product revenue of approximately $44.2 million for the first quarter ended March 31, 2026, representing a 168% increase compared to the same period in 2025, according to a company statement.

The biotechnology company said the revenue figure reflects continued adoption of its ANKTIVA treatment by urologists in the United States. The quarterly revenue also represents a 15% sequential increase from the $38.3 million earned in the fourth quarter of 2025.

For the full year 2025, ImmunityBio reported net product revenue of $113 million, marking a 700% increase over 2024. Unit sales volume for ANKTIVA increased 168% in the first quarter of 2026 compared to the first quarter of 2025.

The company ended the quarter with an estimated $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026.

ANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries. The treatment was included in updated NCCN Clinical Practice Guidelines in March 2026 for BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease.

ImmunityBio said its pivotal BCG-naïve trial (QUILT-2.005) reached full enrollment, with the Independent Data Monitoring Committee confirming adequate statistical power. The company stated that a supplemental biologics license application submission remains on track for 2026.

The financial figures represent preliminary estimates and may differ from actual results when the company files its quarterly report on Form 10-Q, the company noted.